i-SENS Secures Belgian Reimbursement for CareSens Air CGM
South Korean biosensor manufacturer i-SENS has received official approval for its CareSens Air continuous glucose monitoring (CGM) system to be included in the Belgian national health insurance reimbursement list. This regulatory milestone allows patients in Belgium to receive coverage for the device, significantly reducing out-of-pocket costs and expanding the company’s footprint in the European diabetes care market.
What is the significance of the Belgian reimbursement approval?
The inclusion of CareSens Air in the Belgian health insurance scheme confirms the device meets the stringent clinical and safety standards required by the National Institute for Health and Disability Insurance (INAMI). For patients, this approval shifts the device from a private-pay product to a state-subsidized medical necessity. According to i-SENS, the move is a strategic step in their broader efforts to compete with established global CGM providers in Europe, such as Dexcom and Abbott, by offering a more cost-effective alternative without compromising on sensor accuracy.
How does CareSens Air compare to market incumbents?
The CGM market is currently dominated by high-profile systems like the Dexcom G7 and the Abbott FreeStyle Libre series. CareSens Air distinguishes itself through its compact form factor and its integration with the company’s existing digital health ecosystem.
| Feature | CareSens Air | Industry Standard (Typical) |
|---|---|---|
| Sensor Duration | 15 Days | 10–14 Days |
| Calibration | Factory Calibrated | Factory Calibrated |
| Form Factor | Ultra-slim/Lightweight | Varies |
While industry leaders often rely on established brand loyalty, i-SENS is leveraging its history as a long-term blood glucose monitoring (BGM) provider to build trust with endocrinologists. By securing reimbursement, the company bypasses the primary barrier to adoption—price—allowing patients to choose their device based on clinical performance rather than financial constraints.
What are the next steps for i-SENS in Europe?
Following the Belgian approval, i-SENS management, led by CEOs Cha Geun-sik and Nam Hak-hyun, is focusing on scaling distribution networks across Western Europe. The company is currently navigating the regulatory environments of neighboring countries, aiming to replicate the Belgian model. Expanding reimbursement access is essential for the company to meet its growth targets in the medical technology sector, as European public health systems act as the primary gatekeepers for high-volume patient adoption.
Key Takeaways
- Market Access: CareSens Air is now eligible for reimbursement under Belgium’s national health insurance, lowering the barrier for entry for local diabetic patients.
- Competitive Strategy: i-SENS is positioning its 15-day sensor life as a key differentiator against competitors offering 10 or 14-day cycles.
- Regulatory Growth: The move signals a broader push by the South Korean firm to solidify its presence in the European Union, following successful CE-MDR certification.
The shift toward integrated, state-supported digital health solutions remains a priority for European regulators. By aligning with INAMI’s requirements, i-SENS has secured a stable revenue channel that provides predictable growth compared to the volatility of direct-to-consumer medical device sales.